| Bioactivity | NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity[1]. | ||||||||||||
| Target | AMPA receptor | ||||||||||||
| Invitro | NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex[1]. | ||||||||||||
| In Vivo | NBQX (FG9202; 20 mg/kg, i.p.; for 3 days) decreases seizures induced by PTZ[2]. NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion[1]. Animal Model: | ||||||||||||
| Name | NBQX | ||||||||||||
| CAS | 118876-58-7 | ||||||||||||
| Formula | C12H8N4O6S | ||||||||||||
| Molar Mass | 336.28 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014 Sep; 19(8):1174-84. [2]. Wen Chen, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016 Nov 23;11(11):e0166672. |